Table 2

Response rate, PFS, and OS in the VMPT-VT and VMP arms and by renal cohorts

MeasureVMPT-VT arm, estimated glomerular filtration rate
VMP arm, estimated glomerular filtration rate
Total (n = 232)≤ 30 (n = 14)31-50 (n = 56)≤ 50 (n = 70)> 50 (n = 162)Total (n = 241)≤ 30 (n = 19)31-50 (n = 60)≤ 50 (n = 79)> 50 (n = 162)
Response-evaluable, n 221 11 52 63 158 235 19 58 77 158 
Response rate, % 93.2 81.8a 96.2b 93.7c 93d 83 68.4 81 77.9 85.4e 
CR rate, % 39.4 36.4f 42.3g 41.3h 38.6i 25.5 15.8 25.9 23.4 26.6j 
Median time to first response, mo 1.4 1.2k 1.4l 1.4m 1.4n 1.4 1.4 1.4 1.4 1.4o 
Median duration of response, mo NR 19.8p NRq NRr NRs 27.9 20 22 21.8 28.6t 
Median PFS, mo NR 20.9 NR NR NR 24.6 22.5 24.2 24.2 25.1 
1-year PFS, % 93 80 96 96 92 87 83 89 87 87 
2-year PFS, % 69 40 73 69 69 55 46 57 54 56 
Median OS, mo NR NR NR NR NR NR NR NR NR NR 
1-year OS, % 92.3 75.2 94.2 90.7 93 93.8 88.9 93.1 92.1 95.3 
2-year OS, % 88 60.2 89.6 84.2 89.6 89.3 83.3 88.7 87.3 90.3 
MeasureVMPT-VT arm, estimated glomerular filtration rate
VMP arm, estimated glomerular filtration rate
Total (n = 232)≤ 30 (n = 14)31-50 (n = 56)≤ 50 (n = 70)> 50 (n = 162)Total (n = 241)≤ 30 (n = 19)31-50 (n = 60)≤ 50 (n = 79)> 50 (n = 162)
Response-evaluable, n 221 11 52 63 158 235 19 58 77 158 
Response rate, % 93.2 81.8a 96.2b 93.7c 93d 83 68.4 81 77.9 85.4e 
CR rate, % 39.4 36.4f 42.3g 41.3h 38.6i 25.5 15.8 25.9 23.4 26.6j 
Median time to first response, mo 1.4 1.2k 1.4l 1.4m 1.4n 1.4 1.4 1.4 1.4 1.4o 
Median duration of response, mo NR 19.8p NRq NRr NRs 27.9 20 22 21.8 28.6t 
Median PFS, mo NR 20.9 NR NR NR 24.6 22.5 24.2 24.2 25.1 
1-year PFS, % 93 80 96 96 92 87 83 89 87 87 
2-year PFS, % 69 40 73 69 69 55 46 57 54 56 
Median OS, mo NR NR NR NR NR NR NR NR NR NR 
1-year OS, % 92.3 75.2 94.2 90.7 93 93.8 88.9 93.1 92.1 95.3 
2-year OS, % 88 60.2 89.6 84.2 89.6 89.3 83.3 88.7 87.3 90.3 

PFS and OS were analyzed in all 473 patients.

CR indicates complete response; NR, not reached; OS, overall survival; PFS, progression-free survival; VMP, bortezomib-melphalan-prednisone; and VMPT-VT, bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance.

a

P = .3 for the comparison with VMP patients with eGFR ≤ 30;

b

P = .026 for the comparison with VMP patients with eGFR 31-50;

c

P = .015 for the comparison with VMP patients with eGFR ≤ 50;

d

P = .22 for the comparison with VMPT-VT patients with eGFR31-50 and VMPT-VT patients with eGFR ≤ 30;

e

P = .16 for the comparison with VMP patients with eGFR 31-50 and VMP patients with eGFR ≤ 30;

f

P = .2 for the comparison with VMP patients with eGFR ≤ 30;

g

P = .07 for the comparison with VMP patients with eGFR 31-50;

h

P = .025 for the comparison with VMP patients with eGFR ≤ 50;

i

P = .87 for the comparison with VMPT-VT patients with eGFR31–50 and VMPT-VT patients with eGFR ≤ 30;

j

P = .59 for the comparison with VMP patients with eGFR 31-50 and VMP patients with eGFR ≤ 30;

k

P = .62 for the comparison with VMP patients with eGFR ≤ 30;

l

P = .61 for the comparison with VMP patients with eGFR 31-50;

m

P = .51 for the comparison with VMP patients with eGFR ≤ 50;

n

P = .89 for the comparison with VMPT-VT patients with eGFR 31-50 and VMPT-VT patients with eGFR ≤ 30;

o

P = .82 for the comparison with VMP patients with eGFR 31-50 and VMP patients with eGFR ≤ 30;

p

P = .18 for the comparison with VMP patients with eGFR ≤ 30;

q

P = .47 for the comparison with VMP patients with eGFR 31-50;

r

P = .83 for the comparison with VMP patients with eGFR ≤ 50;

s

P = .41 for the comparison with VMPT-VT patients with eGFR 31-50 and VMPT-VT patients with eGFR < 30; and tP = .57 for the comparison with VMP patients with eGFR 31-50 and VMP patients with eGFR < 30.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal